Insulet Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ashley A. McEvoy
- Full Time Employees
- 5,400
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 100 Nagog Park Acton MA United States of America 01720
- IPO Date
- May 15, 2007
- CIK
- 0001145197
- Website
- insulet.com
- Similar Companies
- Business
- Insulet Corporation (NASDAQ: PODD) is a medical device company that designs, develops, manufactures and commercializes innovative tubeless insulin delivery systems and related products primarily for people with diabetes; its flagship Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitors for automated insulin dosing via a smartphone app or dedicated controller, the Omnipod DASH Insulin Management System featuring Bluetooth-enabled touchscreen control and waterproof tubeless Pods delivering continuous insulin for up to 72 hours without needles, the Omnipod GO pre-filled disposable Pod system for type 2 diabetes patients requiring basal insulin, and the core Omnipod Insulin Management System offering wearable needle-free delivery; the company also pursues applications of its Pod technology for non-insulin subcutaneous drug delivery in other therapeutic areas through its Drug Delivery segment. Headquartered in Acton, Massachusetts, and founded in 2000, Insulet operates highly automated manufacturing facilities with key geographic presence in the US, Europe, Asia Pacific, the Middle East, Australia and select emerging markets including China and Malaysia, serving approximately 500,000 global customers across 25 countries. In recent developments, the company completed acquisitions of automated insulin delivery assets from Bigfoot Biomedical and Automated Glucose Control LLC for $25 million each to bolster its Omnipod 5 technology, announced a proposed $450 million senior unsecured notes offering due 2033 and amendments to its credit agreement extending revolving credit facility maturity to 2030 with commitments increased to $500 million to redeem its 0.375% Convertible Senior Notes due 2026 including the remaining $380 million principal, integrated Omnipod 5 with Dexcom G7 in multiple European markets alongside new CGM reimbursements in Norway, extended its supply agreement with NXP USA effective 2025 for critical manufacturing components, redeemed outstanding convertible notes, and raised its fiscal 2025 revenue growth guidance to 28-29% at constant currency while outlining a long-term strategy targeting 20% revenue CAGR through 2028 driven by global expansion, operational efficiencies and innovation.
Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)
Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care
Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?
Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions
Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor
Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor
Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy?
PODD Stock: What a Hold Rating Says at a $163 Target
US court overturns Insulet's $452 mln insulin-pump trade secret verdict against EOFlow
Insulet to Participate in William Blair 46th Annual Growth Stock Conference
PODD and Omnipod 5: What's Driving Insulet's 2026 Growth
Stock Futures Higher as Micron Stock Extends Rally
Insulet flags dosing defect in some Omnipod devices, sees up to $50 million cost
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets
Insulet Corp (PODD) Shares Surge 3.5% -- What GF Score of 82 Tells Investors
Insulet Corporation (PODD) Presents at Bank of America Global Healthcare Conference 2026 Transcript